ARCHIVES

FDA Approives Lilly’s Alimta For 1st-Line Metastatic NSCLC

This article is from The Cancer Letter archive.

Vol. 31 No. 9 | September 26, 2008

Download PDF Visit The Full Archive

Related Articles

Myriad In Partnership To Market Products.

December 14, 2001

GAO Suggests No Limit On Indirect Costs But Ceiling On Total Costs

September 7, 1979

In Congress: Time Running out On Effort To Double Market Exclusivity Term

November 7, 1997

Cancer Meetings Listed

April 15, 1994

ASCO Recommends End of Life Discussions

January 28, 2011

In Brief: UICC Publishes International directory Of Cancer Centers; HSAs Still Worry NCI

January 7, 1977